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Abstract Caspase-3, a member of the caspase family of cell
death proteases, cleaves cytoplasmic and nuclear substrates and
promotes apoptotic cell death in mammalian cells. Although
yeast homologs of apoptotic genes have not been identified, some
components of apoptotic pathways retain function in yeast. Here
we show that the expression of caspase-3 delays cell growth in
Saccharomyces cerevesiae without causing cell death. Mutation
of the caspase-3 QACRG active site abolished effects on yeast
growth. Co-expression of caspase inhibitors alleviated growth
inhibition in yeast as did the tripeptide caspase inhibitor ZVAD-
fmk. These results suggest that substrates for caspase-3 are
present in S. cerevesiae and may participate in the normal cell
growth and division processes.
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1. Introduction
Caspases are a family of cytoplasmic cysteine endoproteases
that function in cell death pathways in metazoans and higher
organisms [1]. These enzymes are synthesized as inactive zym-
ogens that are activated by proteolytic processing [2]. The
active form of most caspases is composed of two polypeptides
of approximately 20 (p20) and 10 kDa (p10) in a tetrameric
structure of two p20-p10 heterodimers [3^10]. After an apop-
totic stimulus, members of the caspase family are activated
and cleave speci¢c cytoplasmic and nuclear substrates such
as fodrin and poly (ADP-ribose) polymerase (PARP) at pre-
ferred sites containing Asp in the P1 position [2,11,12]. Strin-
gent regulation of caspase activity is likely to be vital for the
cell survival.
A number of viral gene products function as caspase inhib-
itors and have provided important insights into caspase func-
tion and their role in proteolytic processing of caspase pro-
enzymes. For example, the baculovirus p35 protein is a broad
spectrum caspase inhibitor that blocks apoptotic cell death
following any one of multiple stimuli in nematodes, Drosophi-
la and mammalian cells [13,14]. In contrast, the cowpox virus
serpin CrmA inhibits a limited number of apoptosis pathways
as a selective antagonist of caspases 31, 38 and 310 [15^21].
A recently identi¢ed family of proteins called IAPs (inhibitors
of apoptosis) has been characterized with broad activity for
caspases [22^27]. Mammalian IAPs have recently been shown
to inhibit the catalytic activity of three distal caspases (3, 7
and 9) in vitro [28^30]. The IAPs are the only mammalian
proteins as yet shown to be speci¢c inhibitors of caspases,
suggesting that additional inhibitors remain to be discovered.
Single cell eukaryotes are not generally believed to possess
homologous cell death machinery, yet several studies have
described cell death or growth arrest in the yeasts Saccharo-
myces cerevisiae or Schizosaccharomyces pombe following the
expression of the pro-apoptotic Bax and Bak proteins [31^35].
As in mammalian cells, Bcl-2 and Bax are targeted to the
mitochondria and Bax-induced cell death is associated with
mitochondrial release of cytochrome c [36,37]. Bax lethality is
prevented by the co-expression of anti-apoptotic Bcl-2 family
members, suggesting that the molecular targets for certain cell
death components are shared between yeast and metazoans
[35,38].
Bax-induced killing in S. cerevisiae has been incorporated in
a genetic screen for suppressors of Bax function [39,40]. Two
isolates in the Bax screen have been described, the mammalian
BI-1/TEGT gene encoding a resident ER protein and the yeast
F0/F1 subunit ATPase 4 gene. These genes have comparable
e¡ects on mammalian apoptosis, demonstrating the utility of
yeast-based screens for investigating cell death pathways in
higher eukaryotes. However, since caspase inhibitors do not
prevent Bax lethality in S. cerevisiae or S. pombe, Bax/Bcl-2-
based screens will not identify apoptosis components that act
on the caspase proteolysis pathway [35]. As for the Bcl-2 gene
family, searches of the yeast genome database have not iden-
ti¢ed homologs of caspases. Despite this apparent lack of
endogenous caspases in yeast, potential caspase cleavage sites
are found in S. cerevisiae proteins (unpublished, MW and
DH) and may function as substrates if exogenous active casp-
ases are expressed. A recent report of the expression of pro-
caspase-3 in the methylotrophic yeast Pichia pastoris described
an inhibitory e¡ect on cell growth.
In this report, we describe the e¡ects of caspase-3 expres-
sion in S. cerevisiae. Caspase-3 expression in yeast is not le-
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thal, but it impairs cell growth. This growth inhibition is
dependent on intact protease function, since either mutation
of the active site cysteine, co-expression of an optimized
CrmA caspase inhibitor or treatment with the broad spectrum
caspase inhibitor ZVAD-£uoro-methyl ketone reverse casp-
ase-3 growth inhibition in S. cerevisiae. Since caspase-3 func-
tions, like those of Bax, may be recapitulated in yeast should
allow rapid genetic or small compound-based screens for in-
hibitors of apoptotic pathways in higher eukaryotes.
2. Materials and methods
2.1. Yeast cell culture and transformations
All yeast strains were maintained on an appropriate dropout me-
dium to select for plasmid marker expression. The yeast strains used
in these studies were W303-1A (MATa ade-2-1 his3-11 his3-15 leu2-3
leu2-112 trp1-1 ura3-1) (kindly provided by Dr. Ted Young) and
EGY48 (MATK trp1 ura3 his3 leu2: :(lexA operators)6 -LEU2) (kindly
provided by Dr. Roger Brent). Transformations were performed using
the lithium acetate method using a total of 4^6 Wg of yeast plasmid
with 100 Wg of sheared salmon sperm DNA. One tenth of each trans-
formation reaction was plated onto selective media. ZVAD-fmk was
resuspended in DMSO at 10 mM. It was applied to the yeast plates at
a ¢nal concentration of 20 Wm prior to plating of transformed yeast
cells. Also colony growth was assessed at 96 h. For measurements of
cell viability, cells were collected at 24 h intervals following plating
and tested for their ability to exclude trypan blue. At least 300 cells
were scored as live versus dead for each measurement.
2.2. Cloning of caspase-3 into yeast and bacterial expression vectors
The large 17 kDa subunit (amino acids 28^175) and the small 10
kDa subunit (amino acids 176^277) of caspase-3 were subcloned by
polymerase chain reaction (PCR) from a human caspase-3 cDNA
(pcDNA3) into the pYX233 (TRP1) and pYX213 (URA3) yeast ex-
pression vectors (Novagen), respectively, using standard recombinant
DNA technologies (Maniatis). The mutant large 17 kDa subunit was
generated using a two step PCR mutagenesis method that changed the
amino acid cysteine-163 to glycine. The CrmA and CrmA-mut
cDNAs were subcloned by PCR from pcDNA3 CrmA and pBlue-
script KS(+) CrmA-mut vectors into the pYX122 (HIS3) yeast ex-
pression vector (Novagen). For expression and quanti¢cation of re-
combinant protein, caspase-3 (amino acids 28^277) and CrmA were
subcloned by PCR into pET28a(+) bacterial expression vector with
the addition of a C-terminal His-6 tag (Novagen). CrmA-mut was
excized from pBluescript KS(+) CrmA-mut as a SacI-HindIII Ubp
fragment and ligated to pRSET A histidine-tagged bacterial expres-
sion vector (Invitrogen) and linearized. All constructs were sequenced
for authenticity and shown to be in frame. The details of the primer
sequences used for PCR cloning will be provided upon request.
2.3. Immunoblotting assays
Overnight 100 ml cultures of caspase-3-transformed cells grown in
2% ra⁄nose media were diluted to an OD600 of 0.8 into 2% galactose-
containing media to induce caspase-3 expression. 10 ml aliquots were
centrifuged at 5000 rpm and the cell pellet was washed twice with
sterile de-ionized water. The yeast cells were resuspended in lysis bu¡-
er (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1% Triton X-100, 0.1%
SDS, 1 mM EDTA) with a protease inhibitor cocktail tablet (Boehr-
inger, Mannheim) added immediately before using equal volumes of
acid-washed 4 mm glass beads were added to each sample followed by
vortexing for 2 min at room temperature. The protein content was
quantitated using the Bio-Rad protein assay. The samples, containing
50 Wg of protein, were resolved on a 12% SDS-polyacrylamide gel.
The gel was transferred to nitrocellulose membranes and probed with
an anti-caspase-3 polyclonal antibody (Santa Cruz) according to the
manufacturer’s instructions. 2 Wg of puri¢ed recombinant caspase-3
was included as a positive control.
2.4. Expression and puri¢cation of His-tagged caspase-3, CrmA and
CrmA-mut protein
The pET28a(+) caspase-3, pET28a(+) CrmA and pRSET A CrmA-
mut bacterial expression plasmids were transformed into BL21(DE3)
(Novagen) cells for protein expression and puri¢cation. 5 ml cultures
containing the corresponding plasmids were grown overnight at 30‡C.
The following morning the overnight culture was diluted into a 1 l
culture of Luria broth and grown at 37‡C to an OD660 of 0.8. Iso-
propyl L-D-thiogalactopyranoside was added to each culture to a ¢nal
concentration of 1 mM. Cultures were grown for an additional 3 h at
25‡C. The cells were harvested and histidine-tagged fusion proteins
were puri¢ed by a nickel chromatograph using a Qiagen Ni-NTA
protein puri¢cation kit. Coomassie blue staining of SDS-polyacryl-
amide gels was used to determine the purity of the recovered proteins.
2.5. In vitro caspase-3 cleavage assays
[35S]-labelled CrmA-mut protein was prepared from the pRSET A
CrmA-mut plasmid by in vitro transcription and translation using a
Promega TNT T7 transcription/translation kit. All caspase-3 cleavage
reactions were performed in a bu¡er containing 20 mM Pipes, 100
mM NaCl, 10% sucrose and 10 mM dithiothreitol. 200 ng of recombi-
nant caspase-3 was incubated with 3 Wl of [35S]methionine-labelled
CrmA-mut protein in a total volume of 20 Wl. 200 ng aliquots of
recombinant caspase-3 were incubated with the indicated amounts
of puri¢ed CrmA or CrmA-mut protein at 30‡C for 15 min followed
by the addition of 3 Wl of in vitro translated [35S]methionine-labelled
CrmA-mut protein. After an additional h at 37‡C the samples were
subjected to 15% SDS-PAGE. The gel was dried and exposed to
Kodak X-Omat AR X-ray ¢lm for 24 h at room temperature.
3. Results
We focused on studying the e¡ects of caspase-3 in S. cere-
visiae since previous studies have shown it to be an essential
caspase required for mammalian apoptosis [41^43]. Caspase-3
preferentially cleaves DEVD-containing substrates and is ac-
tivated as a central component in a proteolytic cascade in
most, if not all, models of apoptosis [44]. Transient expression
of pro-caspase-3 in Sf9 insect cells results in apoptosis, pre-
sumably as a consequence of autocatalytic proteolytic proc-
essing [45].
We initially inserted the cDNA encoding the 32 kDa casp-
ase-3 pro-enzyme into the pYX243(LEU2) 2-micron yeast ex-
pression plasmid under the control of the GALx promoter.
Galactose-induced expression of full length caspase-3 zymo-
gen in yeast did not result in a detectable autoactivation of
caspase-3 as judged by the appearance of processed large (17
kDa) and small (10 kDa) subunits (unpublished, MW), in
contrast to a previous report in P. pastoris, and did not impair
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Fig. 1. Time course of caspase-3 expression in galactose media.
W303-1A cells containing both the pYX233-p17 (TRP1) and
pYX213-p10 (URA3) subunits of caspase-3 were grown overnight in
YNB tryptophan- and uracil-de¢cient liquid media containing 2%
ra⁄nose. Cells were diluted to an OD660 of 0.8 into 2% galactose
YNB tryptophan- and uracil-de¢cient liquid media to induce expres-
sion of the caspase-3 subunits. 10 ml aliquots of yeast cells were
processed at the indicated time as described in Section 2. 50 Wg of
yeast lysate was loaded per lane and resolved on a 12% SDS-poly-
acrylamide gel. 2 Wg of puri¢ed recombinant caspase-3 was loaded
as a positive control.
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yeast growth or survival [46]. To circumvent the lack of casp-
ase-3 autoactivation, we co-expressed the large and small sub-
units from separate plasmids to allow the intracellular assem-
bly of active protease. cDNA fragments encoding the 17 and
10 kDa caspase-3 subunits were cloned into the 2-micron
yeast episomal expression vectors pYX233 (TRP1) and
pYX213(URA3), respectively, with each subunit under the
control of the galactose-inducible GAL1 promoter. Using an
antibody that recognizes the x, expression of the 17 kDa sub-
unit was observed in galactose-containing media by 6 h (Fig.
1). Co-transformation with plasmids encoding each subunit of
active caspase-3 resulted in no colonies on galactose plates
(Fig. 2A). Colony formation in S. cerevisiae was similar to
the vector controls when either the p17 or p10 subunit of
caspase-3 was expressed alone (data not shown). To determine
whether this e¡ect was dependent on protease activity, we
mutated the active site cysteine-163, which lies within the
highly conserved QACRG pentapeptide sequence of the large
subunit, to a glycine [41,45,47]. The expression of this mutant
pYX233-p17 caspase-3 subunit with the normal pYX213 p10
subunit resulted in colony formation on galactose, compara-
ble to vector controls (Fig. 2B).
To determine if the caspase-3 phenotype in yeast was due to
cell killing, we compared the viability of transformants on
galactose and glucose media by trypan blue dye exclusion.
Viability of the two cultures over a 72 h period was greater
than 90% under both conditions (Fig. 3A). However, a sig-
ni¢cant growth delay was evident for caspase-3-expressing
cells in galactose media relative to glucose media when viable
cell counts were compared (Fig. 3B). Thus, caspase-3 fails to
induce cell death in S. cerevisiae but hinders cell growth. Mu-
tant caspase-3 expression resulted in normal growth kinetics
in liquid culture (Fig. 3A).
As an additional test for the requirement of speci¢c casp-
ase-3 protease activity in the yeast growth delay, we co-ex-
pressed caspase-3 with the cowpox virus serpin CrmA, or a
modi¢ed version referred to as CrmA-mut [48]. CrmA is a
potent inhibitor for caspases 1, 4 and 8, but relatively ine¡ec-
tive for caspases 2,3,6,7 and 10 and the C.elegans caspase
homolog CED-3. While CrmA is a poor inhibitor of casp-
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Fig. 3. Caspase-3 expression in yeast inhibits growth. (A) W303-1A
colonies containing pYX233-p17(TRP1) and pYX213-p10(URA3)
caspase-3 subunits were picked from tryptophan- and uracil-de¢cient
glucose plates and re-streaked onto tryptophan- and uracil-de¢cient
plates containing 2% glucose or galactose. Approximately 200 yeast
cells were scored using trypan blue in triplicate at the speci¢ed time
points. The results represent the percentage of yeast cells excluding
trypan blue and are given as the mean þ S.D. These data are repre-
sentative of at least three independent experiments. (B) Fresh yeast
colonies containing wild-type or mutant caspase-3 plasmids were
picked from a tryptophan- and uracil-de¢cient glucose plate and in-
noculated into 50 ml of YNB tryptophan- and uracil-de¢cient media
containing 2% ra⁄nose. After overnight growth at 30‡C the culture
was centrifuged and the cell pellet washed twice with sterile water.
The cells were diluted to an OD660 of 0.10 into 50 ml of fresh YNB
tryptophan- and uracil-de¢cient media containing 2% galactose. The
OD660 of each culture was measured every 12 h over a 36 h time
period. The data are representative of at least three independent ex-
periments.
Fig. 2. Co-expression of the 17 and 10 kDa subunits of the caspase-
3 enzyme inhibits the yeast growth. (A) W303-1A cells were trans-
formed with the pYX233-p17 (TRP1) and pYX213-p10 (URA3)
plasmids or control pYX233(TRP1) and pYX213 (URA3) plasmids.
Cells were plated onto tryptophan- and uracil-de¢cient plates con-
taining 2% glucose or galactose and incubated at 30‡C for 96 h. (B)
W303-1A cells were co-transformed with the mutant pYX233-
p17(TRP1) and pYX213-p10(URA3) caspase-3 plasmids and incu-
bated as described in Fig. 2A.
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ase-3, CrmA-mut contains a baculovirus p35 cleavage site
inserted into the reactive loop of CrmA. p35 is cleaved by
multiple caspases at this site and the resulting caspase-p35
complex is inactive. The CrmA-mut inhibitor was previously
shown to be cleaved by CED-3 and capable of inhibiting
CED-3 mediated apoptosis in C. elegans, while CrmA could
not [48]. We cloned cDNAs for both inhibitors into the cen-
tromeric pYX122(HIS3) yeast episomal vector which placed
their expression under the constitutive control of the yeast
triose phosphate isomerase promoter. Yeast co-transformed
with the caspase-3 and CrmA plasmids failed to form colonies
on galactose, but growth suppression was relieved when the
CrmA-mut plasmids were introduced with the caspase-3 plas-
mids (Fig. 4A). This result suggests that caspase inhibitors
function similarly in yeast as in animal cells, and that
CrmA-mut is an e¡ective inhibitor of caspase-3. We con-
¢rmed the speci¢city of each inhibitor with an in vitro cleav-
age assay. With [35S]methionine labelled CrmA-mut protein as
a substrate, recombinant caspase-3 produced essentially com-
plete cleavage (Fig. 4B, lane 2). The addition of puri¢ed re-
combinant CrmA-mut protein to the reaction caused a partial
inhibition of this cleavage at a 1:1 molar ratio (Fig. 4B, lane
5) and a complete inhibition at a 2.5:1 molar ratio (Fig. 4B,
lane 6). This is similar to the inhibitory properties of p35,
which also has maximal e¡ects at equimolar ratios with puri-
¢ed recombinant caspase. In contrast, CrmA failed to block
caspase-3 activity even when present at a 10 fold molar excess
(Fig. 4C, lane 8).
We also determined whether ZVAD-£uoro-methyl ketone,
a broad spectrum irreversible caspase inhibitor, could sup-
press the growth defects induced by caspase-3. As shown in
Fig. 5, plating of transformed yeast cells with caspase-3 onto
plates containing 20 WM ZVAD-fmk prevented caspase-3-
mediated growth inhibition.
4. Discussion
While most of the identi¢ed components of cell death path-
ways have regulatory functions, some proteins appear to have
direct cytotoxic activities. Bax, a pro-apoptotic homolog of
Bcl-2, produces apoptotic death after cell transfection with
mitochondrial and microsomal derangements perhaps related
to its function as a membrane channel [49]. The apoptotic
caspase proteases can also have direct cytotoxic functions
and are generally regarded as central executioners for pro-
grammed cell deaths. Transfection of single caspases can
cause apoptotic cell death, following autoprocessing of the
pro-enzyme [45,47,50^55]. We investigated whether, like
Bax, the caspase-3 apoptotic protease is amenable to study
in a heterologous yeast system that appears to lack a compar-
able cell death pathway.
Caspase-3 expression resulted in growth inhibition in S.
cerevisiae, manifested as a delayed colony formation on agar
and slow growth in liquid culture. Growth inhibition de-
pended on the protease activity, as shown by its absence in
yeast containing an active site mutation within the p17 cata-
lytic subunit of caspase-3. Caspase-3 induced growth delay
appeared to be dose-dependent, since co-expression of sub-
units from a low copy number centromeric yeast vector failed
to produce a noticeable e¡ect on S. cerevisiae cell growth
(unpublished, MW). Previous studies have demonstrated
that expression of two other mammalian proteins that pro-
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Fig. 5. The broad spectrum caspase inhibitor ZVAD-fmk alleviates
caspase-3-mediated growth inhibition in yeast. W303-1A cells co-
transformed with the pYX233-p17 (TRP1) and pYX213-p10
(URA3) caspase-3 plasmids were plated onto tryptophan- and ura-
cil-de¢cient galactose or glucose plates containing 20 WM ZVAD-
fmk. The transformed cells were incubated for 96 h at 30‡C. The
data are representative of at least three independent experiments.
Fig. 4. Co-expression of CrmA-mut but not CrmA rescues the yeast
growth defects caused by caspase-3 expression. (A) W303-1A cells
were co-transformed with the pYX233-17 (TRP1) and pYX213-p10
(URA3) caspase-3 plasmids along with the pYX122CrmA3 (HIS3)
or pYX122CrmA-mut (HIS3) plasmids. Transformants were grown
for 96 h at 30‡C on tryptophan-, uracil-, and histidine-de¢cient me-
dia containing glucose or galactose as described in Fig. 2A. (B) 200
ng aliquots of recombinant caspase-3 were incubated with the indi-
cated amounts of puri¢ed CrmA-mut protein at 30‡C for 15 min
followed by the addition of 3 Wl of in vitro translated
[35S]methionine-labelled CrmA-mut protein (CrmA-mut). After an
additional h at 37‡C the samples were subjected to 15% SDS-
PAGE. The gel was dried and exposed to Kodak X-Omat AR X-
ray ¢lm for 24 h at room temperature. (C) 200 ng aliquots of re-
combinant caspase-3 were incubated with the indicated amounts of
puri¢ed CrmA protein at 30‡C for 15 min followed by the addition
of 3 Wl of in vitro translated [35S]methionine-labelled CrmA-mut
protein (CrmA-mut). After an additional h at 37‡C the samples
were subjected to 15% SDS-PAGE. The gel was dried and exposed
to Kodak X-Omat AR X-ray ¢lm for 24 h at room temperature.
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mote apoptosis, Bax and Bak, is lethal in yeast. The lack of
cell killing with caspase-3 expression in S. cerevisiae is perhaps
not surprising, since additional caspases cannot be recruited
by a proteolytic cascade in yeast, as they can in mammalian
cells. Bax expression in respiratory-de¢cient yeast strains has
also been reported to cause growth inhibition rather than cell
death, suggesting that expression of other apoptotic factors
may compromise but not curtail cell growth [33]. Interest-
ingly, not all caspases had growth inhibitory e¡ects in yeast.
This is likely to re£ect the functional di¡erences between casp-
ases [56^60]. Speci¢cally, among caspases 2, 3, 6^9 expressed
as active subunits in yeast, only caspase-3 resulted in a severe
growth inhibition in yeast (unpublished, MW and DH). It can
be inferred from these results that substrates for caspase-3
exist in S. cerevisiae and may include endogenous yeast pro-
teins required for cell growth and division. These substrates
may represent homologs of proteins that are cleaved by casp-
ase-3 during mammalian apoptosis, as cleavage sites may be
conserved (unpublished, MW and DH).
We also demonstrated that caspase inhibitors identi¢ed in
higher eukaryotes are functional in S. cerevisiae. The yeast
expression system discriminated between CrmA and CrmA-
mut proteins as caspase inhibitors. These proteins are identi-
cal, except for the substitution of the amino acid sequence
DQMDGFHD within the reactive cleavage loop of CrmA
(aa 300^307: LVADCAST) [48]. The eight amino acid se-
quence in CrmA-mut is derived from the reactive cleavage
site of the p35 baculovirus protein, which is preferentially
cleaved by caspase-3-like proteases [61]. Previous studies dem-
onstrated that CrmA-mut, but not CrmA, inhibited pro-
grammed cell death in C. elegans, consistent with its enhanced
ability to be cleaved by the CED-3 protease in vitro [48].
CrmA and p35 are suicide inhibitors that form a stable pro-
tease-inhibitor complex after their cleavage. CED-3 and casp-
ase-3 have similar substrate speci¢cities and our results dem-
onstrate that CrmA-mut is a better in vivo inhibitor of
caspase-3 in yeast and in vitro inhibitor in the cleavage assay
[60].
The broad spectrum caspase inhibitor ZVAD-fmk inhibits
apoptosis in mammalian cells initiated by di¡erent stimuli,
including the Fas family of death receptors and DNA damag-
ing agents. The diversity of cell deaths inhibited by ZVAD-
fmk underscores the signi¢cance of caspase activity during
apoptosis. The yeast growth defect induced by caspase-3 ex-
pression was reversible with 20 WM ZVAD-fmk, a concentra-
tion routinely used to block mammalian cell culture models of
apoptosis [62]. This result strongly suggests that the ZVAD-
fmk moiety crosses the yeast cell membrane and maintains its
inhibitory activity intracellularly. Therefore, this caspase-3 ex-
pression system in S. cerevisiae should prove to be useful for
testing small compounds or screening mammalian cDNA ex-
pression libraries for novel caspase-3 inhibitors.
Acknowledgements: We thank Dr. Vishva Dixit for his generous gift
of the pcDNA3 caspase-3 plasmid and Drs. Robert Horvitz and Ding
Xue for the pBluescript KS CrmA-mut plasmid and Ann Koning for
the stimulating discussions and critical review of the manuscript.
References
[1] Salvesen, G.S. and Dixit, V.M. (1997) Cell 91, 443^446.
[2] Miller, D.K. (1997) Semin. Immunol. 9, 35^49.
[3] Darmon, A.J., Nicholson, D.W. and Bleackley, R.C. (1995) Na-
ture 377, 446^448.
[4] Quan, L.T., Tewari, M., O’Rourke, K., Dixit, V., Snipas, S.J.,
Poirier, G.G., Ray, C., Pickup, D.J. and Salvesen, G.S. (1996)
Proc. Natl. Acad. Sci. USA 93, 1972^1976.
[5] Gu, Y., Sarnecki, C., Aldape, R.A., Livingston, D.J. and Su,
M.S. (1995) J. Biol. Chem. 270, 18715^18718.
[6] Muzio, M., Chinnaiyan, A.M., Kischkel, F.C., O’Rourke, K.,
Shevchenko, A., Ni, J., Sca⁄di, C., Bretz, J.D., Zhang, M.,
Gentz, R., Mann, M., Krammer, P.H., Peter, M.E. and Dixit,
V.M. (1996) Cell 85, 817^827.
[7] Duan, H., Orth, K., Chinnaiyan, A.M., Poirier, G.G., Froelich,
C.J., He, W.W. and Dixit, V.M. (1996) J. Biol. Chem. 271,
16720^16724.
[8] Walker, N.P., Talanian, R.V., Brady, K.D., Dang, L.C., Bump,
N.J., Ferenz, C.R., Franklin, S., Ghayur, T., Hackett, M.C. and
Hammill, L.D. (1994) Cell 78, 343^352.
[9] Wilson, K.P., Black, J.A., Thomson, J.A., Kim, E.E., Gri⁄th,
J.P., Navia, M.A., Murcko, M.A., Chambers, S.P., Aldape, R.A.
and Raybuck, S.A. (1994) Nature 370, 270^275.
[10] Rotonda, J., Nicholson, D.W., Fazil, K.M., Gallant, M., Ga-
reau, Y., Labelle, M., Peterson, E.P., Rasper, D.M., Ruel, R.,
Vaillancourt, J.P., Thornberry, N.A. and Becker, J.W. (1996)
Nat. Struct. Biol. 3, 619^625.
[11] Song, Q., Burrows, S.R., Smith, G., Lees-Miller, S.P., Kumar, S.,
Chan, D.W., Trapani, J.A., Alnemri, E., Litwack, G., Lu, H.,
Moss, D.J., Jackson, S. and Lavin, M.F. (1996) J. Exp. Med.
184, 619^626.
[12] Chinnaiyan, A.M., Hanna, W.L., Orth, K., Duan, H., Poirier,
G.G., Froelich, C.J. and Dixit, V.M. (1996) Curr. Biol. 6, 897^
899.
[13] Clem, R.J., Hardwick, J.M. and Miller, L.K. (1996) Cell Death
Di¡er. 3, 9^16.
[14] Beidler, D.R., Tewari, M., Friesen, P.D., Poirier, G. and Dixit,
V.M. (1995) J. Biol. Chem. 270, 16526^16528.
[15] Zhou, Q., Snipas, S., Orth, K., Muzio, M., Dixit, V.M. and
Salvesen, G.S. (1997) J. Biol. Chem. 272, 7797^7800.
[16] Vincenz, C. and Dixit, V.M. (1997) J. Biol. Chem. 272, 6578^
6583.
[17] Gagliardini, V., Fernandez, P.A., Lee, R.K.K., Drexler, H.C.A.,
Rotello, R.J., Fishman, M.C. and Yuan, J. (1994) Science 263,
826^828.
[18] Miura, M., Friedlander, R.M. and Yuan, J. (1995) Proc. Natl.
Acad. Sci. USA 92, 8318^8322.
[19] Tewari, M., Telford, W.G., Miller, R.A. and Dixit, V.M. (1995)
J. Biol. Chem. 270, 22705^22708.
[20] Tewari, M. and Dixit, V.M. (1995) J. Biol. Chem. 270, 3255^
3260.
[21] Marsters, S.A., Pitti, R.M., Donahue, C.J., Ruppert, S., Bauer,
K.D. and Ashkenazi, A. (1996) Curr. Biol. 6, 750^752.
[22] Crook, N.E., Clem, R.J. and Miller, L.K. (1993) J. Virol. 67,
2168^2174.
[23] Birnbaum, M.J., Clem, R.J. and Miller, L.K. (1994) J. Virol. 68,
2521^2528.
[24] Roy, N., Mahadevan, M.S., McLean, M., Shutler, G., Yaraghi,
Z., Farahani, R., Bair, S., Besner-Johnston, A., Lefebvre, C. and
Kang, X. (1995) Cell 80, 167^178.
[25] Rothe, M., Pan, M.G., Henzel, W.J., Ayres, T.M. and Goeddel,
D.V. (1995) Cell 83, 1243^1252.
[26] Liston, P., Roy, N., Tamai, K., Lefebvre, C., Baird, S., Cherton-
Horvat, G., Farahani, R., McLean, M., Ikeda, J.E., MacKenzie,
A. and Korneluk, R.G. (1996) Nature 379, 349^353.
[27] Uren, A.G., Pakusch, M., Hawkins, C.J., Puls, K.L. and Vaux,
D.L. (1996) Proc. Natl. Acad. Sci. USA 93, 4974^4978.
[28] Deveraux, Q.L., Takahashi, R., Salvesen, G.S. and Reed, J.C.
(1997) Nature 388, 300^304.
[29] Roy, N., Deveraux, Q.L., Takahashi, R., Salvesen, G.S. and
Reed, J.C. (1997) EMBO J. 16, 6914^6925.
[30] Deveraux, Q.L., Roy, N., Stennicke, H.R., Van Arsdale, T.,
Zhou, Q., Srinivascula, S.M., Alnemri, E.S., Salvesen, G.S. and
Reed, J.C. (1998) EMBO J. 17, 2215^2223.
[31] Sato, T., Hanada, M., Bodrug, S., Irie, S., Iwama, N., Boise,
L.H., Thompson, C.B., Golemis, E., Fong, L., Wang, H.-G.
and Reed, J.C. (1994) Proc. Natl. Acad. Sci USA 91, 9238^
9242.
FEBS 21630 5-3-99
M.E. Wright et al./FEBS Letters 446 (1999) 9^14 13
[32] Sato, T., Hanada, M., Bodrug, S., Irie, S., Iwama, N., Boise,
L.H., Thompson, C.B., Golemis, E., Fong, L., Wang, H.-G.
and Reed, J.C. (1995) Proc. Natl. Acad. Sci. USA 92, 1793.
[33] Greenhalf, W., Stephan, C. and Chaudhari, B. (1996) FEBS Lett.
380, 169^175.
[34] Ink, B., Zornig, M., Baum, B., Hajibagheri, N., James, C., Chit-
tenden, T. and Evan, G. (1997) Mol. Cell. Biol. 17, 2468^2474.
[35] Jurgensmeier, J.M., Krajewski, S., Armstrong, R.C., Wilson,
G.M., Oltersdorf, T., Fritz, L.C., Reed, J.C. and Ottilie, S.
(1997) Mol. Biol. Cell 8, 325^339.
[36] Zha, H., Fisk, H.A., Ya¡e, M.P., Mahajan, N., Herman, B. and
Reed, J.C. (1996) Mol. Cell. Biol. 16, 6494^6508.
[37] Manon, S., Chaudhari, B. and Buerin, M. (1997) FEBS Lett. 415,
29^32.
[38] Shaham, S., Shuman, M.A. and Herskowitz, I. (1998) Cell 92,
425^427.
[39] Xu, Q. and Reed, J.C. (1998) Mol. Cell. Biol. 1, 337^346.
[40] Matsuyama, S., Xu, Q., Velours, J. and Reed, J.C. (1998) Mol.
Cell. Biol. 1, 327^336.
[41] Nicholson, D.W., Ali, A., Thornberry, N.A., Vaillancourt, J.P.,
Ding, C.K., Gallant, M., Gareau, Y., Gri⁄n, P.R., Labelle, M.
and Lazebnik, Y.A. (1995) Nature 376, 37^43.
[42] Kumar, S. (1997) Int. J. Biochem. Cell. Biol. 29, 393^396.
[43] Schlegel, J., Peters, I., Orrenius, S., Miller, D.K., Thornberry,
N.A., Yamin, T.T. and Nicholson, D.W. (1996) J. Biol. Chem.
271, 1841^1844.
[44] Talanian, R.V., Quinlan, C., Trautz, S., Hackett, M.C., Manko-
vich, J.A., Banach, D., Ghayur, T., Brady, K.D. and Wong,
W.W. (1997) J. Biol. Chem. 272, 9677^9682.
[45] Fernandez-Alnemri, T., Litwack, G. and Alnemri, E.S. (1994)
J. Biol. Chem. 269, 30761^30764.
[46] Sun, J., Bottomley, S.P., Kumar, S. and Bird, P.I. (1997) Bio-
chem. Biophys. Res. Commun. 238, 920^924.
[47] Tewari, M., Quan, L.T., O’Rourke, K., Desnoyers, S., Zeng, Z.,
Beidler, D., Poirier, G.G., Salvesen, G.S. and Dixit, V.M. (1995)
Cell 81, 801^809.
[48] Xue, D. and Horvitz, H.R. (1995) Nature 377, 248^251.
[49] Xiang, J., Chao, D.T. and Korsmeyer, S.J. (1996) Proc. Natl.
Acad. Sci. USA 93, 14559^14563.
[50] Miura, M., Zhu, H., Rotello, R., Hartwieg, E.A. and Yuan, J.
(1993) Cell 75, 653^660.
[51] Kumar, S., Kinoshita, M., Noda, M., Copeland, N.G. and Jen-
kins, N.A. (1994) Genes Dev. 8, 1613^1626.
[52] Wang, L., Miura, M., Bergeron, L., Zhu, H. and Yuan, J. (1994)
Cell 78, 739^750.
[53] Faucheu, C., Diu, A., Chan, A.W., Blanchet, A.M., Miossec, C.,
Herve, F., Collard-Dutilleul, V., Gu, Y., Aldape, R.A., Lippke,
J.A., Rocher, C., Su, M.S.-S., Livingston, D.J., Hercend, T. and
Lalanne, J.-L. (1995) EMBO J. 14, 1914^1922.
[54] Kamens, J., Paskind, M., Hugunin, M., Talanian, R.V., Allen,
H., Banach, D., Bump, N., Hackett, M., Johnston, C.G., Li, P.,
Mankovich, J.A., Terranova, M. and Ghayur, T. (1995) J. Biol.
Chem. 270, 15250^15256.
[55] Fernandez-Alnemri, T., Litwack, G. and Alnemri, E.S. (1995)
Cancer Res. 55, 2737^2742.
[56] Takahashi, A., Alnemri, E.S., Lazebnik, Y.A., Fernandes-Alnem-
ri, T., Litwack, G., Moir, R.D., Goldman, R.D., Poirier, G.G.,
Kaufmann, S.H. and Earnshaw, W.C. (1996) Proc. Natl. Acad.
Sci. USA 93, 8395^8400.
[57] Janicke, R.U., Ng, P., Sprengart, M.L. and Porter, A.G. (1998)
J. Biol. Chem. 273, 15540^15545.
[58] Chandler, J.M., Cohen, G.M. and MacFarlane, M. (1998) J. Biol.
Chem. 273, 10815^10818.
[59] Hirata, H., Takahashi, A., Kobayashi, S., Yonehara, S., Sawai,
H., Okazaki, T., Yamamoto, K. and Sasada, M. (1998) J. Exp.
Med. 187, 587^600.
[60] Thornberry, N.A., Rano, T.A., Peterson, E.P., Rasper, D.M.,
Timkey, T., Garcia-Calvo, M., Houtzager, V.M., Nordstrom,
P.A., Roy, S., Vaillancourt, J.P., Chapman, K.T. and Nicholson,
D.W. (1997) J. Biol. Chem. 272, 17907^17911.
[61] Bump, N.J., Hackett, M., Hugunin, M., Seshagiri, S., Brady, K.,
Chen, P., Ferenz, C., Franklin, S., Ghayur, T. and Li, P. (1995)
Science 269, 1885^1888.
[62] Livingston, D.J. (1997) J. Cell. Biochem. 64, 19^26.
FEBS 21630 5-3-99
M.E. Wright et al./FEBS Letters 446 (1999) 9^1414
